HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,006,684 | +4.7% | 52,531 | -1.2% | 1.11% | +13.1% |
| Q2 2023 | $1,917,193 | -17.1% | 53,152 | -12.2% | 0.98% | -24.2% |
| Q1 2023 | $2,311,908 | -0.8% | 60,537 | +47.8% | 1.29% | -10.7% |
| Q4 2022 | $2,330,453 | +45.5% | 40,957 | +1.1% | 1.45% | +34.6% |
| Q3 2022 | $1,602,000 | – | 40,508 | – | 1.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Third Security, LLC | 19,829,337 | $266,308,000 | 10.60% |
| BB BIOTECH AG | 6,929,832 | $93,068,000 | 2.95% |
| SECTORAL ASSET MANAGEMENT INC | 2,671,051 | $35,872,000 | 1.64% |
| Sterling Global Strategies LLC | 22,000 | $295,000 | 1.63% |
| Lombard Odier Asset Management (USA) Corp | 1,061,547 | $14,257,000 | 1.24% |
| PYRRHO CAPITAL MANAGEMENT, LP | 90,000 | $1,209,000 | 1.04% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 8,184,003 | $109,911,000 | 0.93% |
| Bellevue Asset Management AG | 246,000 | $3,304,000 | 0.54% |
| Convergence Investment Partners, LLC | 251,748 | $3,381,000 | 0.39% |
| Rhenman & Partners Asset Management AB | 172,000 | $2,310,000 | 0.37% |